<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778297</url>
  </required_header>
  <id_info>
    <org_study_id>FluvalAB-H-05</org_study_id>
    <secondary_id>OGYI 28438/82/07</secondary_id>
    <secondary_id>EudraCT 2007-004239-52</secondary_id>
    <nct_id>NCT00778297</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine</brief_title>
  <official_title>Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine With 6 Mcg HA/Strain/Dos Antigen Content</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluart Innovative Vaccine Ltd, Hungary</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluart Innovative Vaccine Ltd, Hungary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single blind, reference drug controlled, one center viral immunogenicity and
      tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos
      antigen content to assess immunogenicity and tolerability.

      The aim of the study is to assess the immunogenicity and tolerability of FluvalAB FL-K-004
      trivalent influenza vaccine with 6 μg HA/strain/dos antigen content (study drug) in age
      groups 18-60 years and over 60 years, with the objective to verify efficacy and tolerability
      of the study drug according to CPMP/BWP/214/96: &quot;Note for Guidance on Harmonization of
      Requirements for Influenza Vaccines&quot;, 12 March 1997.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-vaccination HI antibody titre</measure>
    <time_frame>21-28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>21-28 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-vaccination HI antibody titer</measure>
    <time_frame>110-120 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with FluvalAB FL-K-004 trivalent flu vaccine</intervention_name>
    <description>Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with FluvalAB trivalent influenza vaccine</intervention_name>
    <description>Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult volunteers in good health aged over 18 years, both sexes;

          -  Full contractual capacity of the participants;

          -  Are in good health (as determined by vital signs and medical history);

          -  Negative urine or serum pregnancy test for females of childbearing potential;

          -  Are able to understand and comply with planned study procedures;

          -  Signed informed consent prior to initiation of study procedures;

          -  Absence of existence of any exclusion criteria.

        Exclusion Criteria:

          -  Known allergy to eggs or other components of the vaccine;

          -  History of Guillain-Barré syndrome;

          -  Pregnancy or breast feeding or positive pregnancy test prior to vaccination;

          -  Immunosuppressive therapy in the preceding 36 months;

          -  Active neoplasm (i.e. requiring any form of anti-neoplastic therapy);

          -  Concomitant corticosteroid therapy, including inhaled corticosteroids;

          -  Psychiatric illness and/or concomitant psychiatric drug therapy;

          -  Immunoglobulin (or similar blood product) therapy within 3 months prior to
             vaccination;

          -  Vaccine therapy within 4 weeks prior to the study;

          -  Influenza vaccination within 6 months prior to the study;

          -  Chronic illness that, in the opinion of the investigator, may interfere with the
             evaluation of the immune response;

          -  Documented HIV, HBV or HCV infection;

          -  Acute febrile respiratory illness within one week prior to vaccination;

          -  Experimental drug therapy within 1 month prior to vaccination;

          -  Alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferenc Tamás, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pilisvörösvár District Doctor's Office</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zsuzsa Galambos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Omninvest Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pilisvörösvár District Doctor's Office</name>
      <address>
        <city>Pilisvörösvár</city>
        <zip>2085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>influenza</keyword>
  <keyword>infection</keyword>
  <keyword>vaccine</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Influenza in humans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

